Nonsteroidal anti-inflammatory drug effectivity in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis

Imagem de Miniatura
Arquivos
art_SERRANO_Nonsteroidal_antiinflammatory_drug_effectivity_in_preventing_postendoscopic_retrograde_2020.PDF (2.64 MB)
Citações na Scopus
Tipo de produção
article
Data de publicação
2020
DOI
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BAISHIDENG PUBLISHING GROUP INC
Autores
ROMANINI, Samuel Galante
AGUILAR, Paul Fernando Guaman
CASTRO, Juliana Silveira Lima de
TORRES, Isabela Trindade
PULLA, Jose Andres Sanchez
NETO, Otavio Micelli
TAGLIERI, Eloy
Citação
WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY, v.12, n.11, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND Endoscopic retrograde cholangiopancreatography (ERCP) is the primary therapeutic procedure for the treatment of diseases affecting the biliary tree and pancreatic duct. Although the therapeutic success rate of ERCP is high, the procedure can cause complications, such as acute pancreatitis [post-ERCP pancreatitis (PEP)], bleeding and perforation. AIM To assess the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) in preventing PEP during follow-up. METHODS Databases such as MEDLINE, EMBASE and Cochrane Central Library were searched. Only randomized controlled trials (RCTs) comparing the efficacy of NSAIDs and placebo for the prevention of PEP were included. Outcomes evaluated included the incidence of PEP, severity of pancreatitis, route of administration, types, dose, and timing of administration of NSAIDs. RESULTS Twenty-six RCTs were considered eligible with a total of 8143 patients analyzed. Overall, 4020 patients used NSAIDs before ERCP and 4123 did not use NSAIDs (control group). Ultimately, 298 cases of post-ERCP acute pancreatitis were diagnosed in the NSAID group and 484 cases in the placebo group. The risk of PEP was lower in the NSAID group risk difference (RD): -0.04; 95% confidence interval (CI): -0.07 to - 0.03; number needed to treat (NNT), 25; P < 0.05. NSAID use effectively prevented mild pancreatitis compared to placebo use (2.5% vs 4.1%; 95%CI: -0.05 to -0.01; NNT, 33; P < 0.05), but information on moderate PEP and severe PEP could not be fully elucidated. Only rectal administration reduced the incidence of PEP with RD: -0.06; 95%CI: -0.08 to -0.04; NNT, 17; P < 0.05). Furthermore, only the use of diclofenac or indomethacin was effective in preventing PEP, at a dose of 100 mg, which must be administered before performing ERCP. CONCLUSION Rectal administration of diclofenac and indomethacin significantly reduced the risk of developing mild PEP. Additional RCTs are needed to compare the efficacy between NSAID routes of administration in preventing PEP.
Palavras-chave
Pancreatitis, Endoscopic retrograde cholangiopancreatography, Diclofenac, Indomethacin, Rectal
URI
https://observatorio.fm.usp.br/handle/OPI/39483
Referências
  1. Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779
  2. Bhatia V, 2011, J CLIN GASTROENTEROL, V45, P170, DOI 10.1097/MCG.0b013e3181eb600e
  3. Chandrasekhara V, 2017, GASTROINTEST ENDOSC, V85, P32, DOI 10.1016/j.gie.2016.06.051
  4. Cheon YK, 2007, GASTROINTEST ENDOSC, V66, P1126, DOI 10.1016/j.gie.2007.04.012
  5. Dobronte Z, 2014, WORLD J GASTROENTERO, V20, P10151, DOI 10.3748/wjg.v20.i29.10151
  6. Dumonceau JM, 2020, ENDOSCOPY, V52, P127, DOI 10.1055/a-1075-4080
  7. Elmunzer BJ, 2012, NEW ENGL J MED, V366, P1414, DOI 10.1056/NEJMoa1111103
  8. Andrade-Davila VF, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0314-2
  9. Freeman ML, 2001, GASTROINTEST ENDOSC, V54, P425, DOI 10.1067/mge.2001.117550
  10. Hauser G, 2017, SURG ENDOSC, V31, P602, DOI 10.1007/s00464-016-5004-9
  11. Hosseini M, 2016, ARCH IRAN MED, V19, P538, DOI 0161908/AIM.004
  12. Ishiwatari H, 2016, DIGEST DIS SCI, V61, P3292, DOI 10.1007/s10620-016-4251-x
  13. Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
  14. Kato K, 2017, PANCREAS, V46, P880, DOI 10.1097/MPA.0000000000000852
  15. Katoh T, 2020, J GASTROEN HEPATOL, V35, P1247, DOI 10.1111/jgh.14948
  16. Khoshbaten M, 2008, J GASTROEN HEPATOL, V23, pE11, DOI 10.1111/j.1440-1746.2007.05096.x
  17. Leerhoy B, 2016, SCAND J GASTROENTERO, V51, P1007, DOI 10.3109/00365521.2016.1172338
  18. Levenick JM, 2016, GASTROENTEROLOGY, V150, P911, DOI 10.1053/j.gastro.2015.12.040
  19. Li L, 2019, SCAND J GASTROENTERO, V54, P793, DOI 10.1080/00365521.2019.1623306
  20. Loza AM, 2007, REV ESP ENFERM DIG, V99, P330
  21. Lua GW, 2015, DIGEST DIS SCI, V60, P3118, DOI 10.1007/s10620-015-3609-9
  22. Mansour-Ghanaei F, 2016, WORLD J GASTROENTERO, V22, P5114, DOI 10.3748/wjg.v22.i21.5114
  23. Masjedizadeh A, 2017, GASTROENTEROL REV, V12, P271, DOI 10.5114/pg.2017.72102
  24. Moher D, 2010, INT J SURG, V8, P336, DOI [10.1016/j.ijsu.2010.02.007, 10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
  25. Murray B, 2003, GASTROENTEROLOGY, V124, P1786, DOI 10.1016/S0016-5085(03)00384-6
  26. Onofrio FD, 2017, SURG ENDOSC, V31, P2317, DOI 10.1007/s00464-016-5234-x
  27. Otsuka T, 2012, J GASTROENTEROL, V47, P912, DOI 10.1007/s00535-012-0554-7
  28. Park SW, 2015, ENDOSCOPY, V47, P33, DOI 10.1055/s-0034-1390743
  29. Patai A, 2015, J CLIN GASTROENTEROL, V49, P429, DOI 10.1097/MCG.0000000000000168
  30. Serrano JPR, 2019, ENDOSC INT OPEN, V7, pE477, DOI 10.1055/a-0862-0215
  31. Sajid MS, 2015, WORLD J GASTRO ENDOS, V7, P1341, DOI 10.4253/wjge.v7.i19.1341
  32. Sakai P, 2015, TRATADO ENDOSCOPIA D
  33. Senol A, 2009, WORLD J GASTROENTERO, V15, P3999, DOI 10.3748/wjg.15.3999
  34. Sotoudehmanesh R, 2007, AM J GASTROENTEROL, V102, P978, DOI 10.1111/j.1572-0241.2007.01165.x
  35. Ucar R, 2016, TURK J MED SCI, V46, P1059, DOI 10.3906/sag-1502-104
  36. Vandervoort J, 2002, GASTROINTEST ENDOSC, V56, P652, DOI 10.1067/mge.2002.129086
  37. Yokoe M, 2015, J HEPATO-BIL-PAN SCI, V22, P405, DOI 10.1002/jhbp.259

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/37